Scholarlink

<p>Although emerging evidence links exosomal miRNAs to autoimmunity, the specific role of CD4 + T cell-derived exosomal miRNAs in systemic lupus erythematosus (SLE) remains incompletely understood. This study aimed to identify key exosomal miRNAs derived from CD4 + T cells in SLE and to assess their diagnostic and therapeutic potential. We found that CD4 + T cell-derived exosomal miR‑223‑3p was downregulated in SLE patients and demonstrated moderate diagnostic performance (AUC = 0.71, 95% CI: 0.65–0.77). When combined with conventional clinical markers, it provided incremental diagnostic value. Its correlation with clinical markers (C3/C4) was specific to the CD4 + T cell-derived exosomal fraction, distinguishing it from the plasma‑derived counterpart. Functionally, miR-223-3p overexpression inhibited the secretion of inflammatory cytokines and T cell apoptosis while promoting mitophagy via FBXW7. Additionally, it disrupted pathological T‑B cell interactions by suppressing BAFF and CD19 expression. In a murine lupus model (NZBWF1/J), administration of exosomal miR‑223‑3p alleviated lupus nephritis, as evidenced by reduced proteinuria, lower Anti‑dsDNA titers, and diminished renal immune complex deposition. Collectively, our study identified CD4 + T cell-derived exosomal miR‑223‑3p as a cell-origin-associated biomarker in SLE, while also acting as a pathogenic regulator through the FBXW7/mitophagy axis and modulation of T-B cell crosstalk. Its therapeutic efficacy in vivo supports its potential as a candidate for exosome‑based therapy in SLE, but the evidence remains preliminary.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CD4 + T cell-derived exosomal miR-223-3p serves as a potential biomarker for systemic lupus erythematosus and attenuates lupus nephritis in NZBWF1/J mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Shu-Zhen Xu,
  • Peng Wang,
  • Sha-Sha Tao,
  • Hai-Fen Wei,
  • Yu-Tong Tan,
  • Xiao-Xiao Li,
  • Xiao-Ke Yang,
  • Hui-Hui Shen,
  • Guo-Cui Wu,
  • Hai-Feng Pan

摘要

Although emerging evidence links exosomal miRNAs to autoimmunity, the specific role of CD4 + T cell-derived exosomal miRNAs in systemic lupus erythematosus (SLE) remains incompletely understood. This study aimed to identify key exosomal miRNAs derived from CD4 + T cells in SLE and to assess their diagnostic and therapeutic potential. We found that CD4 + T cell-derived exosomal miR‑223‑3p was downregulated in SLE patients and demonstrated moderate diagnostic performance (AUC = 0.71, 95% CI: 0.65–0.77). When combined with conventional clinical markers, it provided incremental diagnostic value. Its correlation with clinical markers (C3/C4) was specific to the CD4 + T cell-derived exosomal fraction, distinguishing it from the plasma‑derived counterpart. Functionally, miR-223-3p overexpression inhibited the secretion of inflammatory cytokines and T cell apoptosis while promoting mitophagy via FBXW7. Additionally, it disrupted pathological T‑B cell interactions by suppressing BAFF and CD19 expression. In a murine lupus model (NZBWF1/J), administration of exosomal miR‑223‑3p alleviated lupus nephritis, as evidenced by reduced proteinuria, lower Anti‑dsDNA titers, and diminished renal immune complex deposition. Collectively, our study identified CD4 + T cell-derived exosomal miR‑223‑3p as a cell-origin-associated biomarker in SLE, while also acting as a pathogenic regulator through the FBXW7/mitophagy axis and modulation of T-B cell crosstalk. Its therapeutic efficacy in vivo supports its potential as a candidate for exosome‑based therapy in SLE, but the evidence remains preliminary.

Graphical Abstract